Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023

Anavex to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023

Long-term Clinical Study Demonstrates Disease-Modifying Effects of ANAVEX®2-73 for Rett Syndrome

Anavex Life Sciences and Partex Group Announce Strategic Partnership

Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

ANAVEX®2-73 Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome

Anavex Life Sciences Reports Publication in Medical Journal for Continued Commitment to Improve RSBQ

Completion of ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

ANAVEX Announces New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine)

Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023